Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-072568
Filing Date
2025-05-15
Accepted
2025-05-15 16:05:24
Documents
66
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q clsd-20250331.htm   iXBRL 10-Q 1264356
2 EX-31.1 clsd-ex31_1.htm EX-31.1 15562
3 EX-31.2 clsd-ex31_2.htm EX-31.2 15278
4 EX-32.1 clsd-ex32_1.htm EX-32.1 10415
5 GRAPHIC img143322133_0.jpg GRAPHIC 395021
6 GRAPHIC img143322133_1.jpg GRAPHIC 193582
  Complete submission text file 0000950170-25-072568.txt   7531127

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT clsd-20250331.xsd EX-101.SCH 1157212
68 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20250331_htm.xml XML 838482
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37783 | Film No.: 25952667
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)